Lower endometrial receptivity in HIV-infected women receiving oocyte donation: a comorbidity of HIV infection?

Abstract STUDY QUESTION Are the reproductive outcomes of HIV-infected donor oocyte recipient women comparable to those of non-infected women? SUMMARY ANSWER HIV-infected women have lower clinical pregnancy and live birth rates than non-infected women. WHAT IS ALREADY KNOWN The literature on the effect of HIV infection on reproductive outcome is scarce at best; the only report to date comparing oocyte donation cycles in HIV-infected women versus non-infected controls found no differences in pregnancy rates between the two groups. However, this study was performed nearly a decade ago and did not evaluate the effect of immuno-virological characteristics of oocyte recipients or the HIV antiretroviral therapy effect. STUDY DESIGN SIZE, AND DURATION This is a matched-cohort study including 514 oocyte donation cycles, 257 from HIV-infected women and 257 non-infected controls, performed between April 2004 and November 2014. PARTICIPANTS/MATERIALS, SETTING, AND METHOD Each cycle of an HIV-infected woman (n = 257) was matched with a cycle of a non-infected woman (1:1). Biochemical pregnancy, clinical pregnancy, ongoing pregnancy and live birth in the two groups were compared using a multivariate logistic regression analysis. The effect of antiretroviral treatment options on pregnancy outcomes of HIV-infected women was analyzed using a logistic regression model adjusted for time elapsed from diagnosis, and CD4 levels and viral load prior to embryo transfer. MAIN RESULTS AND THE ROLE OF CHANCE Cycles of HIV-infected patients receiving oocyte donation presented lower pregnancy and live birth rates than matched non-infected controls. Treatment options and infection parameters analyzed do not seem to affect the reproductive results in HIV-infected women. The variable most influencing pregnancy outcomes was the number of transferred embryos; lower pregnancy rates were obtained after single embryo transfer. LIMITATIONS REASONS FOR CAUTION Patients with HIV infection have specific health issues, such as infection/treatment side effects, which makes it impossible to find a matching control group of non-infected patients for these variables. WIDER IMPLICATIONS OF THE FINDINGS HIV-infected women receiving donated oocytes present lower pregnancy rates when compared to non-infected controls, regardless of the antiretroviral treatment followed. The complexity of the treatments (both in medication types and combinations) makes it difficult to define whether any one treatment option is better than the others in terms of pregnancy outcomes in oocyte recipients. STUDY FUNDING/COMPETING INTERESTS None. TRIAL REGISTRATION NUMBER Not applicable.

[1]  Dusko Ilic,et al.  Self-organisation of the human embryo in the absence of maternal tissues , 2016, Nature Cell Biology.

[2]  E. Feinberg,et al.  Racial disparities in in vitro fertilization outcomes. , 2015, Fertility and sterility.

[3]  Human immunodeficiency virus (HIV) and infertility treatment: a committee opinion. , 2015, Fertility and sterility.

[4]  Ana-Maria Staicu,et al.  Multilevel Cross‐Dependent Binary Longitudinal Data , 2013, Biometrics.

[5]  C. Brites,et al.  A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management , 2013, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[6]  E. Coast,et al.  Living with HIV postdiagnosis: a qualitative study of the experiences of Nairobi slum residents , 2013, BMJ Open.

[7]  M. Sauer,et al.  Reproductive outcomes of HIV seropositive women treated by assisted reproduction. , 2013, Journal of women's health.

[8]  F. Figueras,et al.  Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART , 2012, AIDS.

[9]  Handan Wand,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[10]  P. Santulli,et al.  HIV-positive patients undertaking ART have longer infertility histories than age-matched control subjects. , 2011, Fertility and sterility.

[11]  D. Jacobs,et al.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.

[12]  O. Coll,et al.  Racial disparity in oocyte donation outcome: a multiethnic, matched cohort study. , 2010, Human reproduction.

[13]  R. Tubiana,et al.  HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. , 2010, Fertility and sterility.

[14]  Jeff G. Wang,et al.  A systematic, multidisciplinary approach to address the reproductive needs of HIV-seropositive women. , 2009, Reproductive biomedicine online.

[15]  Ò. Miró,et al.  Mitochondrial DNA Depletion in Oocytes of HIV-Infected Antiretroviral-Treated Infertile Women , 2008, Antiviral therapy.

[16]  M. Cortina-Borja,et al.  Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006 , 2008, AIDS.

[17]  W. Lewis,et al.  A brief overview of mechanisms of mitochondrial toxicity from NRTIs , 2007, Environmental and molecular mutagenesis.

[18]  M. Gérard,et al.  ART outcome in HIV-infected patients. , 2006, Human reproduction.

[19]  J. Gatell,et al.  Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART , 2006, AIDS.

[20]  J. Gatell,et al.  Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy , 2006, AIDS.

[21]  L. Cravello,et al.  Outcome of ICSI in HIV-1-infected women. , 2005, Human reproduction.

[22]  S. Gregson,et al.  The population impact of HIV on fertility in sub-Saharan Africa , 2004, AIDS.

[23]  L. Shafer,et al.  HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda , 2004, AIDS.

[24]  K. Anastos,et al.  Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV , 2004, AIDS.

[25]  A. Perales,et al.  Duration of ruptured membranes and extended labor are risk factors for HIV transmission , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[26]  C. Rongières,et al.  Assisted reproduction techniques for HIV serodiscordant couples: 18 months of experience. , 2003, Human reproduction.

[27]  J. T. Boerma,et al.  THE ASSOCIATION BETWEEN HIV AND FERTILITY IN A COHORT STUDY IN RURAL TANZANIA , 2003, Journal of Biosocial Science.

[28]  Z. M. van der Spuy,et al.  Endocrine function in HIV-infected women , 2002 .

[29]  P Barrière,et al.  Mitochondrial DNA content affects the fertilizability of human oocytes. , 2001, Molecular human reproduction.

[30]  Swiss Mother Combination antiretroviral therapy and duration of pregnancy , 2000, AIDS.

[31]  L. Kalish,et al.  Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[32]  S. Gortmaker,et al.  Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. , 1999, JAMA.

[33]  R. Sperling,et al.  Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study , 1998, AIDS.

[34]  N. Sewankambo,et al.  Population-based study of fertility in women with HIV-1 infection in Uganda , 1998, The Lancet.

[35]  J. Kaldor,et al.  Fertility and reproductive choice in women with HIV‐1 infection , 1997, AIDS.

[36]  S. Dimauro,et al.  Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy , 1991, The Lancet.

[37]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.